A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia

CD33 is expressed in 90% of patients with acute myeloid leukemia (AML), and its extracellular portion consists of a V domain and a C2 domain. A recent study showed that a single nucleotide polymorphism (SNP), rs12459419 (C > T), results in the reduced expression of V domain–containing CD33 and li...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Nair-Gupta, Priyanka, Diem, Michael, Reeves, Dara, Wang, Weirong, Schulingkamp, Robert, Sproesser, Katrin, Mattson, Bethany, Heidrich, Bradley, Mendonça, Mark, Joseph, Jocelin, Sendecki, Jocelyn, Foulk, Brad, Chu, Gerald, Fink, Damien, Jiao, Qun, Wu, Sheng-Jiun, Packman, Kathryn, Elsayed, Yusri, Attar, Ricardo, Gaudet, François
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Immunobiology and Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065489/
https://ncbi.nlm.nih.gov/pubmed/32150609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001188
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados